期刊
NATURE BIOTECHNOLOGY
卷 26, 期 11, 页码 1227-1233出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt1108-1227
关键词
-
Despite losses in revenue from erythropoietins, historically the highest earner of all biologics, more than 100 biotech drugs continued their upward trend in sales begun in 2006, with antibodies and insulin analogs fueling growth at double-digit rates.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据